novel Cas9 mRNA gene-editing therapy (CureVac/CRISPR)

N/A

Report date: 2025/03/20 09:11:56
NME

Base Information

Drug Namenovel Cas9 mRNA gene-editing therapy (CureVac/CRISPR)
Drug Alias NameN/A
ClassificationSmall molecules > LipidSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsN/A
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermanySwitzerland
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesCureVac NV
China Registration ClassN/A

Develop Information

Active CompaniesCureVac NVCrispr Therapeutics Ag
Inactive CompaniesN/A
Active IndicationsN/A
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A